Clinical Trial: A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07157033) titled 'A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.' on Aug. 28.

Brief Summary: The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.

Study Start Date: Dec. 15, 2025

Study Type: INTERVENTIONAL

Condition: Locally Advanced Pancreatic Adenocarcinoma Locally Advanced Pancreas Cancer Locally Advanced Pancreatic Ductal Adenocarcinoma

Intervention: DRUG: XER-001

XER-001 (Amifostine for nasoduode...